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cedure and for each of the two years post-transplant and
reported in 2003 Canadian dollars. RESULTS: The mean costs
over all periods was $7706 for 876 persons undergoing kidney
transplant, $28,737 for 257 persons undergoing liver transplant,
$43,719 for 67 persons undergoing lung transplant and $31,152
for 133 persons undergoing heart transplant. The largest com-
ponent for all organs was the cost of the procedure and the initial
hospitalization. The mean (SD) costs in the ﬁrst and second post-
discharge years were, respectively, $21,552 (326) and $11,103
(1260) for kidney, $21,146 (1273) and $8090 (535) for liver,
$27,593 (4801) and $11,426 (1144) for lung and $22,588
(1044) and $9777 (520) for heart. Immunosuppresant medica-
tions comprised the largest single cost component during follow-
up. CONCLUSION: There was six-fold variation in direct
medical costs between the least and most expensive solid organ
transplant procedures. The variation in costs diminished between
programs over the ﬁrst and second years post-transplant.
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OBJECTIVES: To estimate the impact of the following Process
optimization (PO) measures implemented during 2002 on case-
related treatment costs (CRTC) in the ICU of a midsize German
hospital, from the hospital perspective: optimization of diagnos-
tic procedures, standardization of medical devices, improved
management of treatment courses, expansion of renal replace-
ment therapies, and replacement of fentanyl/midazolam (FM) 
by remifentanil/propofol (RP) throughout for analgosedation
within a standardized concept for mechanical ventilation.
METHODS: A retrospective cost-consequence analysis was per-
formed comparing 2 intervals: years 2000–2001 before and years
2003–2004 after PO. Data on baseline characteristics, treatment,
outcomes, and resource utilization (staff, laboratory, medical
need) of the ICU cases came from the routine documentation of
the ICU. Resources were valued in 2004 internal hospital prices.
Differences in CRTC and components between the intervals were
regarded signiﬁcant with a p value <0.05. RESULTS: There were
no signiﬁcant differences in baseline characteristics, distribution
of intensive treatment to monitoring, ventilation days, and case-
related mortality between the totals of 1704 and 2044 cases
treated before and after PO, respectively. CRTC, however, sig-
niﬁcantly dropped by 25% from €2435 before to €1815 after
PO, comprising staff expenses (from €1656 to €1238), labora-
tory cost (from €60 to €41), and cost for medical need (from
€718 to €536). The per-case cost for medical need signiﬁcantly
decreased although 2 of its 14 cost categories showed consider-
able increases: cost for renal replacement therapies were 2.9-fold
after PO due to expansion of this kind of treatment and cost 
for analgosedation were 2.1-fold after PO due to using RP
instead of FM. CONCLUSIONS: The whole PO improved 
the efﬁciency as indicated by signiﬁcantly decreased CRTC at
similar case-related mortality. Using RP throughout for anal-
gosedation of mechanically ventilated patients as an integral part
of a comprehensive PO strategy can result in savings of CRTC
in the ICU.
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OBJECTIVES: Although only 7 pharmacoeconomic and 6 
submission guidelines require partial or total budget impact
analyses (BIA), affordability is becoming a key issue to decision-
makers. Our aim was to review the published BIAs according to
different quality assessment criteria. METHODS: PubMed and
EMBASE were searched for articles with the search terms
“budget impact” or “budget analysis” limited to English lan-
guage. Relevant articles were abstracted by aim, funding, tech-
nology and various issues concerning the analyses. RESULTS: 16
studies were found between 2001 and 2006, the majority pre-
pared for pharmaceuticals, and from the US; however, 50% had
BIA only as complementary calculation to economic evaluations.
In the US, due the dominance of private health insurance, and
in France due to the submission requirements, all studies had BIA
as their main aim. Industry funding was stated for 63%;
however, industry afﬁliation was present for a further 13%. In
accordance with the aim of assisting NHS systems and insurance
companies determine affordability, the payer perspective was
chosen in all of the studies, complemented in a few cases by
patient or societal perspective. Direct medical costs (63%) or
only drug costs (19%) were assessed mostly for one year (44%).
Epidemiological data or rate of adoption was mainly based on
literature and assumptions. Results were reported by resource
type in only 6 (38%) studies, even though this would help to
realize a re-deployment of resources. The majority (56%) were
either cost-saving or had cost-saving scenarios. A sensitivity
analysis was done in only half of the studies for BIAs and in a
further 25% for economic evaluation only. CONCLUSIONS:
Although affordability is major issue in health care ﬁnance, BIAs
are still rare and frequently do not seem to generate independent
analyses. The quality of many studies also fails to reach desired
attributes.
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OBJECTIVES: Data from Sweden (Nyren 1992) shows the
annual frequency of consultations for functional dyspepsia (FD)
to be estimated at 47/1000 population with a costs estimated at
$US113,630/1000 population (1991 dollars). No published data
exists for US based employers on the costs associated with FD.
To assess the economic burden of FD associated with medical
costs and work loss from an employer perspective. METHODS:
A review was conducted using a person-centric database con-
taining costs from multiple large geographically diverse US based
employers between 2001–2004. Claims data included pharmacy,
medical, short- and long-term disability (STD, LTD), sick leave
(SL), and productivity measurements. Comparisons were made
between FD employees (ICD-9 code of 536.8) and employees
without FD. Data were compared for a 12-month period begin-
ning 3 months prior to the ﬁrst diagnosis of FD (the index date).
The average index date from the FD cohort was assigned for the
control group. Multiple regression and Markov modeling tech-
niques along with Charlson Co-Morbidity Index to adjust for
